drugset / Trial / NCT04278144
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
Timeline
- Start
- 2020-02-24
- Primary completion
- 2024-12-10
- Completion
- 2025-02-14
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | TRASTUZUMAB IMBOTOLIMOD | Monoclonal antibody | — | — |